8 results about "Dosage schedule" patented technology

A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq / kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit / risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.

Provided are methods for clinical treatment of complement-associated conditions comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (SOLIRIS®) or ravulizumab (ULTOMIRIS®); particularly intravenously administered SOLIRIS® or ULTOMIRIS®.

To provide doses and administrations of anti- C5 antibodies for treating hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).SOLUTION: Methods are provided for clinical treatment of hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), e.g., TMA following HSCT, in human patients using anti- C5 antibodies, or antigen-binding fragments thereof. Provided herein are compositions and methods for treating hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), e.g., TMA following HSCT, in human patients comprising administering to the patients anti- C5 antibodies, or antigen-binding fragments thereof, wherein the anti- C5 antibodies, or antigen-binding fragments thereof, are administered according to (or are for administering according to) a particular clinical dosage regimen (e.g., at a particular dose, according to a defined dosing schedule).SELECTED DRAWING: None

A system is provided.SOLUTION: The system includes a means for evaluating the combination of medicines by using the generated AI, a means for proposing a dosage schedule based on the life rhythm of the user, a means for inputting side effect information by the user, a means for storing the side effect information in a database and periodically feeding back the side effect information to a relevant organization, and a means for managing the remaining amount of the medicine of the user and automatically proposing replenishment.SELECTED DRAWING: Figure 1

Methods are disclosed for electronically labeling and systemically administering radiotracers for targeted diagnostic and therapeutic applications, including immunomodulation. Radiotracers are electronically radiolabeled via direct application to a conductive conductor and delivered systemically through trans-vascular absorption, enabling controlled biodistribution confined to the conductor contact and minimizing off-target exposure. Real-time imaging permits monitoring of radiotracer distribution and activity during administration. Applications include immune modulation for suppression, ablation, or stimulation, as well as activation of non-radioactive precursors for diagnostic and therapeutic use. These methods are applicable to cancer, infectious disease, and autoimmune disorder treatment. Parameters such as radiotracer choice, radioactive activity, precursor formulation, dosing schedule, and administration duration may be adjusted individually or in combination to achieve the desired outcome. These techniques provide reproducible, controllable radiotracer delivery suitable for both imaging and therapy with integrated monitoring.